For the quarter ending 2026-03-31, TXMD made $724K in revenue. $95K in net income. Net profit margin of 13.12%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| License revenue | 724 | 893 | 784 | 952 |
| Selling, general and administrative | - | - | - | 1,551 |
| General and administrative | 1,353 | 2,702 | 1,518 | - |
| Impairment of long-lived assets (note 4) | - | - | - | 0 |
| Write-off and impairment of patents | - | 56 | 32 | 0 |
| Depreciation & amortization | 94 | 97 | 96 | 96 |
| Total operating expenses | 1,447 | 2,855 | 1,646 | 1,647 |
| Loss from operations | -723 | -1,962 | -862 | -695 |
| Interest expense and other financing costs | - | - | 3 | 2 |
| Interest income, net | 41 | 36* | - | - |
| Sublease income | 517 | 1,469* | 534 | 376 |
| Miscellaneous income | 268 | -122* | 381 | 866 |
| Total other income, net | 826 | 1,382 | 912 | 1,240 |
| Income (loss) from continuing operations before income taxes | 103 | -580 | 50 | 545 |
| Income tax benefit | - | - | - | 0 |
| Income (loss) from continuing operations, net of income taxes | 103 | -612 | 50 | 545 |
| Gain from discontinued operations, net of income taxes | -8 | -7 | 102 | 6 |
| Net income (loss) | 95 | -619 | 152 | 551 |
| Basic EPS | 0.01 | -0.053 | 0.01 | 0.05 |
| Diluted EPS | 0.01 | -0.053 | 0.01 | 0.05 |
| Basic Average Shares | 11,574 | 11,576,000 | 11,574,000 | 11,574,000 |
| Diluted Average Shares | 11,640 | 11,576,000 | 11,574,000 | 11,574,000 |
TherapeuticsMD, Inc. (TXMD)
TherapeuticsMD, Inc. (TXMD)